Identification

Name
Fluticasone propionate
Accession Number
DB00588  (APRD00065)
Type
Small Molecule
Groups
Approved
Description

Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma. Fluticasone proprionate is marketed under several different brand names such as Flonase®. Fluticasone propionate is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patients over 12 years old for symptomatic relief of seasonal allergic rhinitis.

Structure
Thumb
Synonyms
Not Available
External IDs
CCI 18781 / CCI-18781 / PF-00241939
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aermony RespiclickPowder, metered232 mcgRespiratory (inhalation)TevaNot applicableNot applicableCanada
Aermony RespiclickPowder, metered113 mcgRespiratory (inhalation)TevaNot applicableNot applicableCanada
Aermony RespiclickPowder, metered55 mcgRespiratory (inhalation)TevaNot applicableNot applicableCanada
ArmonAir RespiClickPowder, metered55 ug/1Respiratory (inhalation)Teva Respiratory, LLC2017-08-07Not applicableUs
ArmonAir RespiClickPowder, metered232 ug/1Respiratory (inhalation)Teva Respiratory, LLC2017-08-07Not applicableUs
ArmonAir RespiClickPowder, metered113 ug/1Respiratory (inhalation)Teva Respiratory, LLC2017-08-07Not applicableUs
CutivateOintment.05 mg/gTopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.2009-12-14Not applicableUs
CutivateCream.5 mg/gTopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.1990-12-18Not applicableUs
CutivateLotion.5 mg/mLTopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.2009-10-05Not applicableUs
CutivateCream0.05 %TopicalGlaxosmithkline Inc2004-11-082013-08-01Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fluticasoneSpray, metered50 mcgNasalApotex Corporation2007-07-05Not applicableCanada
FluticasoneSpray, metered50 ug/1NasalMesource Pharmaceuticals2012-01-09Not applicableUs
FluticasoneSpray, metered50 ug/1NasalMorton Grove Pharmaceuticals, Inc.2012-01-09Not applicableUs
FluticasoneSpray, metered50 ug/1NasalNu Care Pharmaceuticals,inc.2012-01-09Not applicableUs
FluticasoneSpray, metered50 ug/1NasalUnit Dose Services2012-01-09Not applicableUs
FluticasoneSpray, metered50 ug/1NasalDirectrx2014-01-01Not applicableUs
FluticasoneSpray, metered50 ug/1NasalUnit Dose Services2012-01-09Not applicableUs
Fluticasone PropionateSpray, metered50 ug/1NasalProficient Rx LP2006-02-22Not applicableUs
Fluticasone PropionateSpray, metered50 ug/1NasalApotex Corporation2007-09-19Not applicableUs
Fluticasone PropionateSpray, metered50 ug/1NasalPhysicians Total Care, Inc.2006-03-08Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
24 Hour Allergy NasalSpray, metered50 ug/1NasalShopko Stores Operating2016-08-23Not applicableUs
24 Hour Allergy NasalSpray, metered50 ug/1NasalHyvee2016-08-08Not applicableUs
24 Hour Allergy NasalSpray, metered50 ug/1NasalWalgreen2016-05-27Not applicableUs
24 Hour Allergy Relief NasalSpray, metered50 ug/1NasalMeijer Distribution2016-11-17Not applicableUs
24 Hour Allergy Relief nasalSpray, metered50 ug/1NasalKroger2016-05-27Not applicableUs
24hr Nasal Allergy ReliefSpray, metered50 mcgNasalApotex CorporationNot applicableNot applicableCanada
Allergy NasalSpray, metered50 ug/1NasalWalgreen2016-07-12Not applicableUs
Allergy ReliefSpray, metered50 ug/1NasalMeijer Distribution2016-05-27Not applicableUs
Allergy ReliefSpray, metered50 ug/1NasalDiscount Drug Mart2017-07-03Not applicableUs
Allergy Relief NasalSpray, metered50 ug/1NasalPublix Supermarkets, Inc.2016-09-08Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Exchange Select Allergy ReliefSpray, metered50 ug/1NasalArmy + Air Force Exchange Service2017-10-27Not applicableUs
Fluticasone PropionateSpray, metered50 ug/1NasalSelder, S.A. de C.V.2017-05-17Not applicableUs
Fluticasone PropionateSpray, metered50 ug/.1gNasalNu Care Pharmaceuticals,inc.2008-01-16Not applicableUs
International/Other Brands
Ezicas (Intas) / Flixonase (GlaxoSmithKline) / Flixotide (GlaxoSmithKline) / Flovent (GlaxoSmithKline) / FLOVENTHFA / Flunase (GlaxoSmithKline) / Nasofan (Teva) / Pirinase (GlaxoSmithKline) / Seretide (GlaxoSmithKline)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Advair 100 DiskusFluticasone propionate (100 mcg) + Salmeterol (50 mcg)PowderRespiratory (inhalation)Glaxosmithkline Inc1999-09-24Not applicableCanada
Advair 125Fluticasone propionate (125 mcg) + Salmeterol (25 mcg)Aerosol, meteredRespiratory (inhalation)Glaxosmithkline Inc2001-12-21Not applicableCanada
Advair 250Fluticasone propionate (250 mcg) + Salmeterol (25 mcg)Aerosol, meteredRespiratory (inhalation)Glaxosmithkline Inc2001-12-21Not applicableCanada
Advair 250 DiskusFluticasone propionate (250 mcg) + Salmeterol (50 mcg)PowderRespiratory (inhalation)Glaxosmithkline Inc1999-09-24Not applicableCanada
Advair 500 DiskusFluticasone propionate (500 mcg) + Salmeterol (50 mcg)PowderRespiratory (inhalation)Glaxosmithkline Inc1999-09-24Not applicableCanada
Advair DiskusFluticasone propionate (250 ug/1) + Salmeterol xinafoate (50 ug/1)PowderOral; Respiratory (inhalation)Physicians Total Care, Inc.2001-06-21Not applicableUs
Advair DiskusFluticasone propionate (100 ug/1) + Salmeterol xinafoate (50 ug/1)PowderRespiratory (inhalation)Remedy Repack2017-05-10Not applicableUs
Advair DiskusFluticasone propionate (100 ug/1) + Salmeterol xinafoate (50 ug/1)PowderRespiratory (inhalation)Glaxosmithkline Inc2001-02-28Not applicableUs
Advair DiskusFluticasone propionate (250 ug/1) + Salmeterol xinafoate (50 ug/1)PowderRespiratory (inhalation)A S Medication Solutions2001-02-05Not applicableUs
Advair DiskusFluticasone propionate (100 ug/1) + Salmeterol xinafoate (50 ug/1)PowderRespiratory (inhalation)Rebel Distributors2001-02-28Not applicableUs
Categories
UNII
O2GMZ0LF5W
CAS number
80474-14-2
Weight
Average: 500.571
Monoisotopic: 500.184429407
Chemical Formula
C25H31F3O5S
InChI Key
WMWTYOKRWGGJOA-CENSZEJFSA-N
InChI
InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1
IUPAC Name
(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl propanoate
SMILES

Pharmacology

Indication

Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the maintenance treatment of asthma as prophylactic therapy and for patients requiring oral corticosteroid therapy for asthma.

Structured Indications
Pharmacodynamics

Fluticasone is an extremely potent vasoconstrictor and anti-inflammatory agent. Its effectiveness in inhaled forms is due to its direct local effect.

Mechanism of action

Binds to the glucocorticoid receptor. Unbound corticosteroids cross the membranes of cells such as mast cells and eosinophils, binding with high affinity to glucocorticoid receptors (GR). The results include alteration of transcription and protein synthesis, a decreased release of leukocytic acid hydrolases, reduction in fibroblast proliferation, prevention of macrophage accumulation at inflamed sites, reduction of collagen deposition, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability and subsequent edema, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. In the management of asthma, the glucocorticoid receptor complexes down-regulates proinflammatory mediators such as interleukin-(IL)-1, 3, and 5, and up-regulates anti-inflammatory mediators such as IkappaB [inhibitory molecule for nuclear factor kappaB1], IL-10, and IL-12. The antiinflammatory actions of corticosteroids are also thought to involve inhibition of cytosolic phospholipase A2 (through activation of lipocortin-1 (annexin)) which controls the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
UProgesterone receptor
agonist
Human
UCytosolic phospholipase A2
inhibitor
Human
UMineralocorticoid receptor
antagonist
Human
Absorption

The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Bioavailability, intranasal = <2%; Oral bioavailability is negligible and the major circulating entity is an inactive metabolite.

Volume of distribution

IV administration = 4.2 L/kg

Protein binding

91%

Metabolism

Fluticasone propionate is metabolized in the liver by cytochrome P450 3A4-mediated hydrolysis of the 5-fluoromethyl carbothioate grouping. This transformation occurs in 1 metabolic step to produce the inactive 17-(beta)-carboxylic acid metabolite, the only known metabolite detected in man.

Route of elimination

Less than 5% of the oral dose was excreted in the urine as metabolites. The rest of the dose is excreted in the feces and parent drug and metabolites.

Half life

Terminal elimination half-life = 7.8 hours

Clearance

The total blood clearance of fluticasone propionate is high (average, 1,093 mL/min), with renal clearance accounting for less than 0.02% of the total.

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fluticasone propionate.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fluticasone propionate.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluticasone propionate.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fluticasone propionate.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fluticasone propionate.Approved, Withdrawn
AldesleukinFluticasone propionate may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of Fluticasone propionate can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fluticasone propionate.Experimental
AloglutamolThe bioavailability of Fluticasone propionate can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Fluticasone propionate.Experimental
AluminiumThe bioavailability of Fluticasone propionate can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Fluticasone propionate can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Fluticasone propionate can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Fluticasone propionate can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluticasone propionate.Approved
AmiodaroneThe serum concentration of Fluticasone propionate can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BFluticasone propionate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fluticasone propionate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fluticasone propionate.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fluticasone propionate.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Fluticasone propionate.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Fluticasone propionate.Approved, Investigational
AprepitantThe serum concentration of Fluticasone propionate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Fluticasone propionate can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Atorvastatin.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fluticasone propionate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fluticasone propionate.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fluticasone propionate.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Fluticasone propionate.Experimental
BendroflumethiazideFluticasone propionate may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Fluticasone propionate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fluticasone propionate.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Fluticasone propionate.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Fluticasone propionate.Experimental
Bismuth SubcitrateThe bioavailability of Fluticasone propionate can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Fluticasone propionate can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Fluticasone propionate can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Fluticasone propionate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Fluticasone propionate can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fluticasone propionate.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluticasone propionate.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluticasone propionate.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fluticasone propionate.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fluticasone propionate.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Fluticasone propionate.Experimental
BumetanideFluticasone propionate may increase the hypokalemic activities of Bumetanide.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluticasone propionate.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluticasone propionate.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Fluticasone propionate can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Fluticasone propionate can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideFluticasone propionate may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe metabolism of Fluticasone propionate can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fluticasone propionate.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Fluticasone propionate.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Fluticasone propionate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluticasone propionate.Approved, Investigational
CeritinibThe serum concentration of Fluticasone propionate can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Fluticasone propionate.Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fluticasone propionate.Approved, Vet Approved
ChlorothiazideFluticasone propionate may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Fluticasone propionate can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneFluticasone propionate may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Fluticasone propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fluticasone propionate.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Fluticasone propionate can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Fluticasone propionate can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Fluticasone propionate.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotrimazoleThe metabolism of Fluticasone propionate can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Fluticasone propionate can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Fluticasone propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Fluticasone propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Fluticasone propionate.Approved, Investigational
Conjugated estrogensThe serum concentration of Fluticasone propionate can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluticasone propionate.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Fluticasone propionate can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Fluticasone propionate.Investigational
CyclopenthiazideFluticasone propionate may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Fluticasone propionate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Fluticasone propionate can be decreased when it is combined with Dabrafenib.Approved
DaidzeinThe serum concentration of Fluticasone propionate can be increased when it is combined with Daidzein.Experimental
DanazolFluticasone propionate may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Fluticasone propionate can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Fluticasone propionate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Fluticasone propionate can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Demecarium.Approved
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Fluticasone propionate.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fluticasone propionate.Approved, Vet Approved
DienestrolThe serum concentration of Fluticasone propionate can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Fluticasone propionate can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Fluticasone propionate.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluticasone propionate.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Fluticasone propionate.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Fluticasone propionate.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Fluticasone propionate.Experimental
DihydroergotamineThe metabolism of Fluticasone propionate can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Fluticasone propionate can be decreased when combined with Diltiazem.Approved
DistigmineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Donepezil.Approved
DoxycyclineThe metabolism of Fluticasone propionate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Fluticasone propionate can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Fluticasone propionate.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fluticasone propionate.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Fluticasone propionate.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Fluticasone propionate can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Fluticasone propionate can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Fluticasone propionate.Approved
EquolThe serum concentration of Fluticasone propionate can be increased when it is combined with Equol.Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluticasone propionate.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Fluticasone propionate.Approved
ErythromycinThe metabolism of Fluticasone propionate can be decreased when combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Fluticasone propionate can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Fluticasone propionate can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Fluticasone propionate can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Fluticasone propionate can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Fluticasone propionate can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Fluticasone propionate can be increased when it is combined with Estrone.Approved
Etacrynic acidFluticasone propionate may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Fluticasone propionate.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Fluticasone propionate.Experimental
Ethinyl EstradiolThe serum concentration of Fluticasone propionate can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluticasone propionate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fluticasone propionate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fluticasone propionate.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Fluticasone propionate.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Fluticasone propionate.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Fluticasone propionate.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fluticasone propionate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fluticasone propionate.Approved
FenthionThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fluticasone propionate.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Fluticasone propionate.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fluticasone propionate.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Fluticasone propionate.Approved, Withdrawn
FluconazoleThe metabolism of Fluticasone propionate can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Fluticasone propionate.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Fluticasone propionate.Experimental
FluoxymesteroneFluticasone propionate may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fluticasone propionate.Approved, Investigational
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Fluticasone propionate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Fluticasone propionate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fluticasone propionate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Fluticasone propionate can be increased when combined with Fosphenytoin.Approved
FurosemideFluticasone propionate may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Fluticasone propionate can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Fluticasone propionate can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with GI-5005.Investigational
GLPG-0492Fluticasone propionate may increase the fluid retaining activities of GLPG-0492.Investigational
GrepafloxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Fluticasone propionate.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fluticasone propionate.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Fluticasone propionate can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Fluticasone propionate.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluticasone propionate.Approved, Investigational
HydrochlorothiazideFluticasone propionate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideFluticasone propionate may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Fluticasone propionate can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Fluticasone propionate.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fluticasone propionate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Fluticasone propionate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Fluticasone propionate.Approved
IdelalisibThe serum concentration of Fluticasone propionate can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Fluticasone propionate can be decreased when combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Fluticasone propionate.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Fluticasone propionate.Approved
IndapamideFluticasone propionate may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Fluticasone propionate.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fluticasone propionate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fluticasone propionate.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ipidacrine.Experimental
IsavuconazoniumThe metabolism of Fluticasone propionate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Fluticasone propionate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluticasone propionate.Withdrawn
IsradipineThe metabolism of Fluticasone propionate can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Fluticasone propionate can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Fluticasone propionate can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fluticasone propionate.Experimental
KetoconazoleThe serum concentration of Fluticasone propionate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fluticasone propionate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fluticasone propionate.Approved
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Fluticasone propionate.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Fluticasone propionate.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fluticasone propionate.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Fluticasone propionate.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Fluticasone propionate.Experimental
LopinavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fluticasone propionate.Approved, Investigational
LorpiprazoleThe serum concentration of Fluticasone propionate can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Fluticasone propionate can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluticasone propionate.Approved, Investigational
LuliconazoleThe serum concentration of Fluticasone propionate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Fluticasone propionate can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fluticasone propionate.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Fluticasone propionate.Illicit, Investigational, Withdrawn
MagaldrateThe bioavailability of Fluticasone propionate can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Fluticasone propionate can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Fluticasone propionate can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Fluticasone propionate can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluticasone propionate.Approved
Magnesium silicateThe bioavailability of Fluticasone propionate can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Fluticasone propionate can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fluticasone propionate.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluticasone propionate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fluticasone propionate.Approved
MefloquineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fluticasone propionate.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluticasone propionate.Approved
MesteroloneFluticasone propionate may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Fluticasone propionate can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluticasone propionate.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Fluticasone propionate.Experimental
MethallenestrilThe serum concentration of Fluticasone propionate can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideFluticasone propionate may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Fluticasone propionate.Approved, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Fluticasone propionate.Approved
MethyltestosteroneFluticasone propionate may increase the fluid retaining activities of Methyltestosterone.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Fluticasone propionate.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Metoclopramide.Approved, Investigational
MetolazoneFluticasone propionate may increase the hypokalemic activities of Metolazone.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Fluticasone propionate.Experimental
MifepristoneThe serum concentration of Fluticasone propionate can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Minaprine.Approved
MitotaneThe serum concentration of Fluticasone propionate can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluticasone propionate.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Fluticasone propionate.Experimental
MoxestrolThe serum concentration of Fluticasone propionate can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluticasone propionate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluticasone propionate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fluticasone propionate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fluticasone propionate.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Fluticasone propionate.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Nalidixic Acid.Approved, Investigational
NandroloneFluticasone propionate may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateFluticasone propionate may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Fluticasone propionate.Approved, Vet Approved
NefazodoneThe serum concentration of Fluticasone propionate can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fluticasone propionate.Approved
NetupitantThe serum concentration of Fluticasone propionate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Fluticasone propionate can be increased when combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Fluticasone propionate.Approved, Investigational
NicorandilThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Fluticasone propionate.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fluticasone propionate.Approved
NilotinibThe metabolism of Fluticasone propionate can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluticasone propionate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fluticasone propionate.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Norfloxacin.Approved
OlaparibThe metabolism of Fluticasone propionate can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluticasone propionate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluticasone propionate.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Fluticasone propionate.Vet Approved
OsimertinibThe serum concentration of Fluticasone propionate can be increased when it is combined with Osimertinib.Approved
OxandroloneFluticasone propionate may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluticasone propionate.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Oxolinic acid.Experimental
OxymetholoneFluticasone propionate may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fluticasone propionate.Approved, Withdrawn
PalbociclibThe serum concentration of Fluticasone propionate can be increased when it is combined with Palbociclib.Approved
ParaoxonThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fluticasone propionate.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Fluticasone propionate.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Fluticasone propionate can be increased when combined with Pentobarbital.Approved, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Fluticasone propionate.Approved, Investigational, Vet Approved, Withdrawn
PhenobarbitalThe metabolism of Fluticasone propionate can be increased when combined with Phenobarbital.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fluticasone propionate.Approved, Vet Approved
PhenytoinThe metabolism of Fluticasone propionate can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluticasone propionate.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pipemidic acid.Experimental
PiretanideFluticasone propionate may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluticasone propionate.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluticasone propionate.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Fluticasone propionate.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Fluticasone propionate.Approved
Polyestradiol phosphateThe serum concentration of Fluticasone propionate can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideFluticasone propionate may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Fluticasone propionate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fluticasone propionate.Experimental, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Fluticasone propionate.Approved
PrimidoneThe metabolism of Fluticasone propionate can be increased when combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Fluticasone propionate.Experimental
PromestrieneThe serum concentration of Fluticasone propionate can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fluticasone propionate.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Fluticasone propionate.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Fluticasone propionate.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Fluticasone propionate.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Fluticasone propionate can be increased when it is combined with Quinestrol.Approved
QuinethazoneFluticasone propionate may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Rabies virus inactivated antigen, A.Approved
RanolazineThe metabolism of Fluticasone propionate can be decreased when combined with Ranolazine.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fluticasone propionate.Approved, Experimental, Investigational
RifabutinThe metabolism of Fluticasone propionate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Fluticasone propionate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Fluticasone propionate can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Fluticasone propionate.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Rindopepimut.Investigational
RitonavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Fluticasone propionate.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Rosoxacin.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Fluticasone propionate.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Rubella virus vaccine.Approved
RucaparibThe metabolism of Fluticasone propionate can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluticasone propionate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluticasone propionate.Approved, Vet Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Fluticasone propionate.Approved
SaquinavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Fluticasone propionate can be decreased when used in combination with Sarilumab.Approved
SecoisolariciresinolThe serum concentration of Fluticasone propionate can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Fluticasone propionate.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fluticasone propionate.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fluticasone propionate.Investigational
SildenafilThe metabolism of Fluticasone propionate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Fluticasone propionate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Fluticasone propionate can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Fluticasone propionate.Approved
SitafloxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Fluticasone propionate can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Fluticasone propionate.Investigational
St. John's WortThe serum concentration of Fluticasone propionate can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanoloneFluticasone propionate may increase the fluid retaining activities of Stanolone.Illicit, Investigational
StanozololFluticasone propionate may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Fluticasone propionate can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluticasone propionate.Approved
SulfisoxazoleThe metabolism of Fluticasone propionate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Fluticasone propionate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Fluticasone propionate.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Fluticasone propionate.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Fluticasone propionate can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Fluticasone propionate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fluticasone propionate.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Fluticasone propionate can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Fluticasone propionate can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Fluticasone propionate.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluticasone propionate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Fluticasone propionate.Vet Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Fluticasone propionate.Experimental
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluticasone propionate.Approved
TestosteroneFluticasone propionate may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone cypionateThe risk or severity of edema formation can be increased when Testosterone cypionate is combined with Fluticasone propionate.Approved
Testosterone enanthateThe risk or severity of edema formation can be increased when Testosterone enanthate is combined with Fluticasone propionate.Approved
Testosterone propionateFluticasone propionate may increase the fluid retaining activities of Testosterone Propionate.Vet Approved, Withdrawn
Testosterone undecanoateThe risk or severity of fluid retention can be increased when Testosterone undecanoate is combined with Fluticasone propionate.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fluticasone propionate.Approved
TiboloneThe serum concentration of Fluticasone propionate can be increased when it is combined with Tibolone.Approved, Investigational
TiclopidineThe metabolism of Fluticasone propionate can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fluticasone propionate.Investigational
TipranavirThe serum concentration of Fluticasone propionate can be increased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Fluticasone propionate can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fluticasone propionate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fluticasone propionate.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Fluticasone propionate.Approved
TorasemideFluticasone propionate may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluticasone propionate.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fluticasone propionate.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Trichlorfon.Vet Approved
TrichlormethiazideFluticasone propionate may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Fluticasone propionate.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluticasone propionate.Approved
TromethamineThe bioavailability of Fluticasone propionate can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Tubocurarine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Fluticasone propionate.Approved, Investigational, Nutraceutical
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fluticasone propionate.Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VemurafenibThe serum concentration of Fluticasone propionate can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Fluticasone propionate can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Fluticasone propionate can be decreased when combined with Verapamil.Approved
VoriconazoleThe serum concentration of Fluticasone propionate can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinFluticasone propionate may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fluticasone propionate.Approved, Investigational
ZeranolThe serum concentration of Fluticasone propionate can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Fluticasone propionate.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Fluticasone propionate can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fluticasone propionate.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Joseph Kaspi, Oded Arad, Michael Brand, Moty Shookrun, Simona Malka, Mohammed Alnabari, Shalom Hazan, Vlado Malesevic, "Synthesis and powder preparation of fluticasone propionate." U.S. Patent US20060009435, issued January 12, 2006.

US20060009435
General References
Not Available
External Links
Human Metabolome Database
HMDB0014726
KEGG Drug
D01708
PubChem Compound
444036
PubChem Substance
46506140
ChemSpider
392059
BindingDB
50354849
ChEBI
31441
ChEMBL
CHEMBL1473
Therapeutic Targets Database
DAP001039
PharmGKB
PA449686
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Fluticasone_propionate
AHFS Codes
  • 68:04.00 — Adrenals
  • 84:06.00 — Anti-inflammatory Agents
  • 52:08.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
FDA label
Download (159 KB)
MSDS
Download (39 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAsthma Bronchial1
1CompletedNot AvailablePulmonary Disease, Chronic Obstructive1
1CompletedBasic ScienceChronic Obstructive Pulmonary Disease (COPD) / Smoke-related Lung Diseases1
1CompletedDiagnosticAirway Inflammation1
1CompletedDiagnosticAllergic Rhinitis (AR)1
1CompletedScreeningPulmonary Disease, Chronic Obstructive1
1CompletedTreatmentAllergic Rhinitis (AR)4
1CompletedTreatmentAllergic Rhinitis (AR) / Rhinitis, Allergic, Perennial1
1CompletedTreatmentAsthma Bronchial4
1CompletedTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)3
1CompletedTreatmentDiabetes Mellitus (DM) / Healthy Volunteers1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentMild to Moderate Asthma1
1CompletedTreatmentPulmonary Disease, Chronic Obstructive1
1RecruitingTreatmentVocal Fold Nodules1
2Active Not RecruitingTreatmentAsthma Bronchial1
2CompletedNot AvailableAsthma Bronchial1
2CompletedPreventionAllergic Rhinitis (AR)1
2CompletedPreventionCarcinoma, Bronchogenic1
2CompletedTreatmentAllergic Rhinitis (AR) / Rhinitis, Allergic, Seasonal2
2CompletedTreatmentAsthma Bronchial15
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)3
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Disease, Chronic Obstructive1
2CompletedTreatmentEsophagitis1
2CompletedTreatmentObliterative Bronchiolitis1
2CompletedTreatmentOesophagitis, Eosinophilic2
2CompletedTreatmentPulmonary Disease, Chronic Obstructive1
2CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
2Enrolling by InvitationTreatmentPolyps, Nasal1
2RecruitingDiagnosticChronic Obstructive Pulmonary Disease (COPD)1
2RecruitingTreatmentAllergic Rhinitis (AR)1
2RecruitingTreatmentAsthma Bronchial2
2TerminatedPreventionBronchiectasis / Chronic Bronchitis / Pulmonary Diseases1
2TerminatedTreatmentAsthma Bronchial3
2TerminatedTreatmentBronchiolitis1
2TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2TerminatedTreatmentPolyp of Nasal Sinus1
2WithdrawnNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
2WithdrawnTreatmentAsthma Bronchial1
2, 3Not Yet RecruitingTreatmentOesophagitis, Eosinophilic1
2, 3RecruitingTreatmentEosinophilic Esophagitis (EoE) / Eosinophilic Gastrointestinal Disorders (EGIDs)1
2, 3RecruitingTreatmentEosinophilic Gastrointestinal Disorders (EGIDs) / Oesophagitis, Eosinophilic1
3Active Not RecruitingTreatmentOesophagitis, Eosinophilic / Swallowing Disorders1
3CompletedNot AvailableAllergic Rhinitis (AR) / Seasonal Allergic Rhinitis (SAR)1
3CompletedNot AvailableSeasonal Allergic Rhinitis (SAR)1
3CompletedPreventionStridor1
3CompletedTreatmentAllergic Rhinitis (AR)1
3CompletedTreatmentAllergic Rhinitis (AR) / Rhinitis, Allergic, Perennial1
3CompletedTreatmentAllergies / Conjunctivitis / Rhinitis / Rhinoconjunctivitis2
3CompletedTreatmentAsthma Bronchial26
3CompletedTreatmentBronchial Asthma1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)5
3CompletedTreatmentChronic Sinusitis With or Without Nasal Polyps1
3CompletedTreatmentChronic Sinusitis With or Without Nasal Polyps / Chronic Sinusitis: [Nos] or [Ethmoidal] or [Chronic Pansinusitis] or [Sphenoidal] / Polyps, Nasal1
3CompletedTreatmentExercised Induced Asthma1
3CompletedTreatmentOesophagitis, Eosinophilic1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
3CompletedTreatmentPulmonary Disease, Chronic Obstructive1
3CompletedTreatmentSeasonal Allergic Rhinitis (SAR)6
3Not Yet RecruitingTreatmentChronic Rhinosinustis With Polyps1
3RecruitingTreatmentAsthma Bronchial4
3RecruitingTreatmentObstructive Sleep Apnea Syndrome (OSAS)1
3TerminatedPreventionAtopic Dermatitis (AD)1
3TerminatedTreatmentCroup1
3Unknown StatusNot AvailableSeasonal Allergic Rhinitis (SAR)1
3Unknown StatusTreatmentPulmonary Disease, Chronic Obstructive2
3WithdrawnTreatmentAsthma Bronchial1
3WithdrawnTreatmentBronchial Asthma1
3WithdrawnTreatmentChronic Obstructive Pulmonary Disease (COPD)3
4Active Not RecruitingBasic ScienceHealthy Volunteers1
4Active Not RecruitingTreatmentPulmonary Disease, Chronic Obstructive1
4CompletedNot AvailableAsthma Bronchial1
4CompletedNot AvailableOcular Hypertension / Open-angle Glaucoma (OAG)1
4CompletedBasic ScienceAsthma Bronchial1
4CompletedBasic ScienceAsthma Bronchial / Healthy Volunteers1
4CompletedBasic ScienceMild Asthma1
4CompletedDiagnosticAsthma Bronchial1
4CompletedDiagnosticAsthma, Allergic1
4CompletedDiagnosticAsthmatic Smokers / Non-asthmatic Smokers1
4CompletedPreventionAllergic Rhinitis (AR) / Conjunctivitis, Seasonal Allergic1
4CompletedTreatmentAllergic Rhinitis (AR)2
4CompletedTreatmentAllergic Rhinitis (AR) / Asthma Bronchial1
4CompletedTreatmentAllergic Rhinitis (AR) / Rhinitis, Allergic, Perennial1
4CompletedTreatmentAsthma Bronchial29
4CompletedTreatmentAsthma Bronchial / Mild Asthma1
4CompletedTreatmentAsthmatic Patients1
4CompletedTreatmentAtopic Dermatitis (AD)4
4CompletedTreatmentBronchial Asthma1
4CompletedTreatmentBronchiectasis1
4CompletedTreatmentChronic Bronchitis / Lung Diseases, Obstructive / Pulmonary Disease, Chronic Obstructive1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)6
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Depression1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Disease, Chronic Obstructive1
4CompletedTreatmentConjunctivitis, Seasonal Allergic1
4CompletedTreatmentPersistent Asthma1
4CompletedTreatmentPsoriasis1
4CompletedTreatmentPulmonary Disease, Chronic Obstructive3
4CompletedTreatmentRhinitis, Allergic, Perennial / Seasonal Allergic Rhinitis (SAR)2
4CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
4CompletedTreatmentSkin Diseases1
4Enrolling by InvitationTreatmentAsthma Bronchial1
4Not Yet RecruitingTreatmentAllergic Rhinitis (AR) / Allergies / Asthma, Allergic1
4RecruitingBasic ScienceAllergic Rhinitis (AR)1
4RecruitingTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentAllergic Rhinitis (AR) / House Dust Mite Allergy1
4RecruitingTreatmentAsthma Bronchial1
4RecruitingTreatmentAsthmatic Bronchitis / Obstruction Airway / Wheezing / Wheezy Bronchitis1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentOesophagitis, Eosinophilic1
4RecruitingTreatmentPulmonary Disease, Chronic Obstructive1
4TerminatedTreatmentAsthma Bronchial2
4TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4TerminatedTreatmentRhinitis, Allergic, Perennial1
4Unknown StatusTreatmentAsthma Bronchial1
4Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4Unknown StatusTreatmentCream Compared to NB-UVB Alone in Patients With Non-segmental Vitiligo / Evaluation of the Efficacy of UVB and Fluticason Proprionate 0.05% / Patients With Active Non-segmental Vitiligo1
4Unknown StatusTreatmentOesophagitis, Eosinophilic1
4Unknown StatusTreatmentPercentage of Annual Acute Exacerbation / Quality of Life1
4WithdrawnTreatmentAllergic Rhinitis (AR)1
4WithdrawnTreatmentAsthma Bronchial1
Not AvailableCompletedNot AvailableAsthma Bronchial8
Not AvailableCompletedNot AvailableAsthma Bronchial / Atopics1
Not AvailableCompletedNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedNot AvailablePulmonary Disease, Chronic Obstructive2
Not AvailableCompletedNot AvailableRespiratory Disorders2
Not AvailableCompletedNot AvailableRhinitis2
Not AvailableCompletedNot AvailableRhinitis, Allergic, Perennial / Rhinitis, Allergic, Seasonal1
Not AvailableCompletedNot AvailableSmokers / Smoking1
Not AvailableCompletedNot AvailableTobacco Abuse Smoke1
Not AvailableCompletedBasic ScienceAsthma, Allergic1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedBasic ScienceSeasonal Allergic Rhinitis (SAR)1
Not AvailableCompletedDiagnosticAsthma Bronchial1
Not AvailableCompletedPreventionCystic Fibrosis (CF)1
Not AvailableCompletedTreatmentAllergies1
Not AvailableCompletedTreatmentAsthma Bronchial2
Not AvailableCompletedTreatmentAsthma, Allergic / Mild Allergic Asthma1
Not AvailableCompletedTreatmentPolyps, Nasal / Sinusitis1
Not AvailableCompletedTreatmentSuspected Eosinophilic Esophagitis1
Not AvailableNot Yet RecruitingNot AvailableAsthma Bronchial1
Not AvailableNot Yet RecruitingDiagnosticChildhood Asthma1
Not AvailableRecruitingNot AvailableAsthma Bronchial1
Not AvailableRecruitingNot AvailableBronchiolitis Obliterans Syndrome (BOS)1
Not AvailableRecruitingSupportive CareBioavailability Study1
Not AvailableRecruitingTreatmentAsthma Bronchial1
Not AvailableRecruitingTreatmentChronic Lung Diseases / Medication Compliance1
Not AvailableRecruitingTreatmentChronic Rhinosinusitis1
Not AvailableRecruitingTreatmentChronic Rhinosinusitis / Chronic Rhinosinusitis Without Polyps / Endoscopic Sinus Surgery / Oral Steroids1
Not AvailableTerminatedTreatmentAsthma Bronchial1
Not AvailableTerminatedTreatmentAsthma Bronchial / Non-Eosinophilic Asthma1
Not AvailableUnknown StatusNot AvailableOesophagitis, Eosinophilic1
Not AvailableUnknown StatusTreatmentAsthma Bronchial1
Not AvailableUnknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableWithdrawnNot AvailableChronic Obstructive Pulmonary Disease (COPD) / Sleep disorders and disturbances1
Not AvailableWithdrawnTreatmentAsthma Bronchial1
Not AvailableWithdrawnTreatmentVitiligo1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Glaxo group ltd dba glaxosmithkline
  • Altana inc
  • G and w laboratories inc
  • Kv pharmaceutical co
  • Perrigo new york inc
  • Tolmar inc
  • Nycomed us inc
  • Taro pharmaceutical industries ltd
  • Apotex inc richmond hill
  • Hi tech pharmacal co inc
  • Roxane laboratories inc
Packagers
Dosage forms
FormRouteStrength
Aerosol, meteredRespiratory (inhalation)
PowderOral; Respiratory (inhalation)
PowderRespiratory (inhalation)
Powder, meteredRespiratory (inhalation)113 mcg
Powder, meteredRespiratory (inhalation)232 mcg
Powder, meteredRespiratory (inhalation)55 mcg
Powder, meteredRespiratory (inhalation)
Spray, meteredNasal50 mcg
Powder, meteredRespiratory (inhalation)113 ug/1
Powder, meteredRespiratory (inhalation)232 ug/1
Powder, meteredRespiratory (inhalation)55 ug/1
CreamTopical0.05 %
Spray, meteredNasal
Spray, meteredNasal50 ug/1
Aerosol, metered; suspensionNasal50 mcg
PowderRespiratory (inhalation)100 mcg
PowderRespiratory (inhalation)250 mcg
PowderRespiratory (inhalation)50 mcg
PowderRespiratory (inhalation)500 mcg
Powder, meteredRespiratory (inhalation)100 ug/1
Powder, meteredRespiratory (inhalation)250 ug/1
Powder, meteredRespiratory (inhalation)50 ug/1
Aerosol, meteredOral; Respiratory (inhalation)125 mcg
Aerosol, meteredOral; Respiratory (inhalation)250 mcg
Aerosol, meteredOral; Respiratory (inhalation)50 mcg
Aerosol, meteredRespiratory (inhalation)110 ug/1
Aerosol, meteredRespiratory (inhalation)220 ug/1
Aerosol, meteredRespiratory (inhalation)44 ug/1
Aerosol, meteredOral; Respiratory (inhalation)25 mcg
CreamTopical.5 mg/g
CreamTopical.5 mg/1
LotionTopical.5 mg/mL
OintmentTopical.05 mg/g
Spray, meteredNasal50 ug/.1g
Kit
Kit
Spray, meteredNasal93 ug/1
Prices
Unit descriptionCostUnit
Fluticasone propionate powder1500.0USD g
Cutivate 0.05% Lotion 120ml Bottle454.6USD bottle
Advair Diskus 60 500-50 mcg/dose Aerosol Disp Pack328.14USD disp
Advair Diskus 60 250-50 mcg/dose Aerosol Disp Pack249.48USD disp
Flovent HFA 220 mcg/act Aerosol 12 gm Inhaler237.67USD inhaler
Cutivate 0.05% Cream 60 gm Tube217.11USD tube
Advair Diskus 60 100-50 mcg/dose Aerosol Disp Pack200.79USD disp
Advair Diskus 14 500-50 mcg/dose Aerosol Disp Pack156.64USD disp
Flovent HFA 110 mcg/act Aerosol 12 gm Inhaler153.01USD inhaler
Cutivate 0.005% Ointment 60 gm Tube128.28USD tube
Flovent HFA 44 mcg/act Aerosol 10.6 gm Inhaler114.27USD inhaler
Flovent Diskus 60 50 mcg/blist Aerosol Inhaler104.74USD inhaler
Flonase 50 mcg/act Suspension 16 gm Bottle94.59USD bottle
Fluticasone Propionate 50 mcg/act Suspension 16 gm Bottle78.28USD bottle
Cutivate 0.05% Cream 30 gm Tube62.99USD tube
Fluticasone Propionate 0.005% Ointment 60 gm Tube56.27USD tube
Fluticasone Propionate 0.05% Cream 60 gm Tube56.27USD tube
Cutivate 0.005% Ointment 30 gm Tube44.99USD tube
Fluticasone Propionate 0.005% Ointment 30 gm Tube35.67USD tube
Fluticasone Propionate 0.05% Cream 30 gm Tube35.67USD tube
Cutivate 0.005% Ointment 15 gm Tube32.99USD tube
Cutivate 0.05% Cream 15 gm Tube32.99USD tube
Advair hfa 230-21 mcg inhaler25.04USD g
Fluticasone Propionate 0.005% Ointment 15 gm Tube23.14USD tube
Fluticasone Propionate 0.05% Cream 15 gm Tube23.14USD tube
Advair hfa 115-21 mcg inhaler18.13USD g
Flovent hfa 220 mcg inhaler15.54USD g
Advair hfa 45-21 mcg inhaler14.59USD g
Flovent hfa 110 mcg inhaler12.26USD g
Flovent hfa 44 mcg inhaler10.99USD g
Flonase 0.05% nasal spray5.68USD g
Advair 500-50 diskus5.26USD each
Advair 250-50 diskus4.0USD each
Cutivate 0.05% cream3.48USD g
Advair 100-50 diskus3.22USD each
Flovent 250 mcg diskus2.45USD each
Flovent 100 mcg diskus1.83USD each
Flovent 50 mcg diskus1.74USD each
Flovent Diskus 500 mcg/dose Metered Inhalation Powder1.55USD dose
Flovent Diskus 250 mcg/dose Metered Inhalation Powder0.77USD dose
Flovent Hfa 250 mcg/dose Metered Dose Aerosol0.77USD dose
Flovent Hfa 125 mcg/dose Metered Dose Aerosol0.39USD dose
Flovent Hfa 50 mcg/dose Metered Dose Aerosol0.22USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
USRE40045No1993-09-072010-09-07Us
CA2317999No2004-11-092020-09-11Canada
CA2125667No2000-03-132012-12-04Canada
US5873360Yes1996-08-232016-08-23Us
US6446627No1997-12-182017-12-18Us
US6743413Yes2001-12-012021-12-01Us
US6938796Yes1998-07-162018-07-16Us
US6997349Yes1998-07-162018-07-16Us
US6431168Yes1998-12-082018-12-08Us
US7107986Yes1998-12-062018-12-06Us
US7500444Yes2006-08-262026-08-26Us
US6315173Yes1998-06-232018-06-23Us
US7143908Yes1998-07-162018-07-16Us
US6170717Yes1998-06-232018-06-23Us
US7350676Yes1999-02-242019-02-24Us
US7832351Yes2003-12-192023-12-19Us
US6161724Yes1998-07-162018-07-16Us
US6510969Yes1998-06-232018-06-23Us
US6966467Yes1998-06-232018-06-23Us
US6435372Yes1998-07-162018-07-16Us
US7300669No1999-10-202019-10-20Us
US8163723Yes2004-02-292024-02-29Us
US9259428Yes2003-12-132023-12-13Us
US8168620Yes2006-08-242026-08-24Us
US6871646No2001-06-232021-06-23Us
US8978966No2012-01-132032-01-13Us
US6701917No2001-06-232021-06-23Us
US7540282No2003-05-062023-05-06Us
US6748947No2001-06-232021-06-23Us
US8006690No2001-06-232021-06-23Us
US6718972No2001-06-232021-06-23Us
US9216260No2011-06-282031-06-28Us
US8651103No2008-03-262028-03-26Us
US8327844No2003-10-032023-10-03Us
US7975690No2005-08-182025-08-18Us
US6715485No2000-03-032020-03-03Us
US8550073No2009-10-222029-10-22Us
US8978647No2010-12-062030-12-06Us
US9463288No2005-05-192025-05-19Us
US8714149No2012-02-252032-02-25Us
US9616024No2004-09-012024-09-01Us
US9066957No2014-10-062034-10-06Us
US9415008No2014-10-062034-10-06Us
US9731087No2011-05-182031-05-18Us
US9072857No2001-04-102021-04-10Us
US9468727No2000-07-302020-07-30Us
US8522778No2002-05-112022-05-11Us
US8555878No2000-03-202020-03-20Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)272-273 °CNot Available
water solubility0.51 mg/L (insoluble)Not Available
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0114 mg/mLALOGPS
logP3.69ALOGPS
logP3.72ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)13.56ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area80.67 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity121.65 m3·mol-1ChemAxon
Polarizability49.26 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier+0.9701
Caco-2 permeable+0.5417
P-glycoprotein substrateSubstrate0.7099
P-glycoprotein inhibitor IInhibitor0.7192
P-glycoprotein inhibitor IINon-inhibitor0.8636
Renal organic cation transporterNon-inhibitor0.8689
CYP450 2C9 substrateNon-substrate0.868
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.8988
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.798
CarcinogenicityNon-carcinogens0.8901
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3753 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.99
hERG inhibition (predictor II)Non-inhibitor0.6125
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03dl-0497100000-b64248896abdef386eaf

Taxonomy

Description
This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid esters
Direct Parent
Steroid esters
Alternative Parents
Androgens and derivatives / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Thioesters / Secondary alcohols / Carbothioic S-esters / Carboxylic acid esters / Cyclic alcohols and derivatives
show 8 more
Substituents
Steroid ester / Androgen-skeleton / Androstane-skeleton / 3-oxosteroid / Hydroxysteroid / 6-halo-steroid / 9-halo-steroid / Oxosteroid / 3-oxo-delta-1,4-steroid / 11-beta-hydroxysteroid
show 28 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
thioester, propanoate ester, 11beta-hydroxy steroid, steroid ester, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, corticosteroid (CHEBI:31441)

Targets

Details
1. Glucocorticoid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Andersson O, Cassel TN, Gronneberg R, Bronnegard M, Stierna P, Nord M: In vivo modulation of glucocorticoid receptor mRNA by inhaled fluticasone propionate in bronchial mucosa and blood lymphocytes in subjects with mild asthma. J Allergy Clin Immunol. 1999 Apr;103(4):595-600. [PubMed:10200007]
  2. Lumry WR: A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999 Oct;104(4 Pt 1):S150-8. [PubMed:10518812]
  3. Zhang X, Moilanen E, Kankaanranta H: Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol. 2001 Nov 23;431(3):365-71. [PubMed:11730731]
  4. Hogger P, Rohdewald P: Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids. 1994 Oct;59(10):597-602. [PubMed:7878687]
  5. Johnson M: Fluticasone propionate: safety profile. Cutis. 1996 Feb;57(2 Suppl):10-2. [PubMed:8646863]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
Gene Name
PGR
Uniprot ID
P06401
Uniprot Name
Progesterone receptor
Molecular Weight
98979.96 Da
References
  1. Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. [PubMed:16507850]
  2. Austin RJ, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, Uings IJ: Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92. [PubMed:12503693]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Phospholipase a2 activity
Specific Function
Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory...
Gene Name
PLA2G4A
Uniprot ID
P47712
Uniprot Name
Cytosolic phospholipase A2
Molecular Weight
85238.2 Da
References
  1. Sano A, Munoz NM, Sano H, Choi J, Zhu X, Jacobs B, Leff AR: Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils. Am J Respir Crit Care Med. 1999 Jun;159(6):1903-9. [PubMed:10351938]
  2. Myo S, Zhu X, Myou S, Meliton AY, Liu J, Boetticher E, Lambertino AT, Xu C, Munoz NM, Leff AR: Additive blockade of beta 2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate. Eur Respir J. 2004 Apr;23(4):511-7. [PubMed:15083746]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
Gene Name
NR3C2
Uniprot ID
P08235
Uniprot Name
Mineralocorticoid receptor
Molecular Weight
107066.575 Da
References
  1. Austin RJ, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, Uings IJ: Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92. [PubMed:12503693]
  2. Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. [PubMed:16507850]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Pearce RE, Leeder JS, Kearns GL: Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24. [PubMed:16565171]
  2. Murai T, Reilly CA, Ward RM, Yost GS: The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme. Chem Res Toxicol. 2010 Aug 16;23(8):1356-64. doi: 10.1021/tx100124k. [PubMed:20707410]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Pearce RE, Leeder JS, Kearns GL: Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24. [PubMed:16565171]
  2. Murai T, Reilly CA, Ward RM, Yost GS: The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme. Chem Res Toxicol. 2010 Aug 16;23(8):1356-64. doi: 10.1021/tx100124k. [PubMed:20707410]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Pearce RE, Leeder JS, Kearns GL: Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24. [PubMed:16565171]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on January 19, 2018 10:49